AGC will expand its production base of synthetic pharmaceuticals in Spain

TOKYO, April 8, 2022 /PRNewswire/ — AGC Inc. (hereafter “AGC”), a Tokyo-the world’s leading manufacturer of glass, chemicals and high-tech materials, has decided to expand the facilities of AGC Pharma Chemicals Europe SLU (hereinafter “APCE”), a subsidiary of AGC in Spain active in synthetic pharmaceuticals (*1) CDMO (*2) business. A new building with a total area of ​​7,500 m2 will be built on the company site, increasing the current production capacity by 30%. The new facility is expected to enter service in the first half of 2024, with an estimated total investment of around 100 million US dollars.

Logo: https://kyodonewsprwire.jp/img/202204069676-O4-4c6L4e5q

Photo: Planned extension of the site (area framed in yellow)
https://kyodonewsprwire.jp/img/202204069676-O2-1q1wYYTZ

Reference:
CDMO commercial sites of the AGC group
https://kyodonewsprwire.jp/prwfile/release/M000303/202204069676/_prw_PI3fl_7TTl7l2b.jpg

Based on its long history and extensive track record, APCE has integrated AGC’s long-accumulated chemical synthesis technologies, including fluorine handling knowledge, and the company’s contract number is increasing more faster than the synthetic pharmaceutical CDMO market, which is growing at over 7% or more annually. To meet this strong demand, AGC has decided to further increase the capacity of this site, in addition to expanding the facilities by 30% (https://www.agc.com/en/news/detail/1200616_2814.html ) announced in April 2020.

This expansion will include the introduction of facilities for High Potency Active Pharmaceutical Ingredients (HPAPIs) (*3), such as cancer treatment drugs, for which demand has increased in recent years. Additionally, AGC will consider further capacity expansion in the near future as the newly constructed building has additional space for further expansion.

As part of its “AGC plus-2023” medium-term management plan, the AGC Group has positioned its life sciences business, including its agrochemical/synthetic pharmaceutical and biopharmaceutical CDMO services, as one of its strategic activities. The Group aims to develop its sales in the life sciences sector by 44.9 billion yen in 2018 at 135 billion yen in 2022 and 200 billion yen or more in 2025. This investment follows the expansion of AGC Wakasa Chemical’s facilities in November 2021 (https://www.agc.com/en/news/detail/1202588_2814.html ), and the company will continue to make aggressive acquisitions and capital investments in its synthetic agrochemical/pharmaceutical and biopharmaceutical CDMO businesses. The AGC Group will strive to provide its customers in each region with globally unified high-quality services, contributing to the well-being of patients and society as a whole.

Remarks
(*1) Synthetic pharmaceuticals: pharmaceuticals made by chemical synthesis, small molecule pharmaceuticals.
(*2) CDMO: Contract Development & Manufacturing Organization. A business that is engaged on behalf of another business to provide product manufacturing services as well as manufacturing process development.
(*3) Can withstand up to OEB4 (1-10 micrograms/m3)

SOURCE AGC Inc.